Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Zacks.com on MSN24d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals ...
Yahoo Finance23d
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...